Skip to main content

Table 1 Baseline characteristics of the entire cohort according to genotype (n = 180)

From: Hepatitis C virus genotype affects survival in patients with hepatocellular carcinoma

 

Genotype 1 (n = 86)

Genotype 2 (n = 78)

Genotype 3 (n = 16)

Age, year

64.5 (56.5–72.3)

67.5 (60.8–73.0) b

46.0 (40.0–53.0) c

Male gender

63 (73.3%)

52 (66.7%)b

15 (93.8%)

Biopsy for diagnosis

24 (27.9%)

27 (34.6%)

3 (18.8%)

Diabetes

27 (33.4%)

22 (34.9%)

6 (40.0%)

Cirrhosis

77 (89.5%)

68 (87.2%)

16 (100%)

Alcohol > 60 g/day

4 (4.7%)

4 (5.1%)

3 (18.8%)

SVR

15 (17.4%)

18 (23.1%)

2 (12.5%)

SVR before enrollment

5 (5.8%)

7 (9.0%)

0

SVR after enrollment

10 (11.6%)

11 (14.1%)

2 (12.5%)

HCV RNA > 600,000 IU/mL

44 (51.2%)

29 (37.2%)

6 (37.5%)

Creatinine, mg/dL

0.82 (0.70–0.93)

0.80 (0.70–0.92)

0.86 (0.69–0.99)

Bilirubin, mg/dL

0.99 (0.72–1.57)

1.00 (0.75–1.72)b

1.93 (1.32–3.67)c

Platelet, × 109/L

111.5 (71.8–153.8)

105.5 (81.5–132.3)

86.5 (43.8–128.8)

Albumin, g/dL

3.6 (3.2–4.0)

3.5 (3.0–3.9)b

3.0 (2.7–3.6) c

PT-INR

1.12 (1.04–1.20)

1.12 (1.06–1.25)b

1.35 (1.21–1.58) c

Child Pugh B or C

16 (18.2%)

18 (23.1%)

10 (62.5%) c

MELD score

8.0 (7.0–10.3)

9.0 (7.0–11.0) b

12.5 (9.5–16.0) c

Follow-up period (month)

28.7 (11.5–45.6)

31.7 (11.9–64.6) b

15.0 (4.6–34.9)

  1. Abbreviation: HCV hepatitis C virus, PT-INR, prothrombin time- international normalized ratio, SVR sustained virologic response, MELD score Model For End-Stage Liver Disease score
  2. a p < 0.05 genotype 1 vs genotype 2, b p < 0.05 genotype 2 vs genotype 3, c p < 0.05 genotype 1 vs genotype 3 using the Mann-Whitney U-test and Chi-squared test
  3. Data are presented as the median (interquartile range) for continuous data and percentages for categorical data